ResMed boosts European presence with MAP purchase
This article was originally published in Clinica
ResMed, which manufactures products for the diagnosis and treatment of sleep disorders, has bought German company MAP Medizin-Technologie for DM146 million ($69 million) in cash and debt assumption. The acquisition brings ResMed the market leader in Germany, the second largest market for sleep disordered breathing products in the world.
You may also be interested in...
Shortly after wrapping up a Phase III trial for its proposed generic Advair Diskus product in the US, Cipla has won FDA approval for the first generic Proventil HFA product, as it continues to build up steam in the US respiratory market.
The UK's MHRA is looking for manufacturers to submit COVID-19 self-tests that meet minimum and desired criteria for evaluation, after finding its recently purchased 3.5m self-tests failed to meet these standards. Criteria include no requirement for testing knowledge or training or assistance from a healthcare professional in administering or interpreting the results of the test, as well as a 95% accuracy level.
Henlius has struck a deal with Mabxience to market its HLX02 trastuzumab biosimilar in Argentina, Uruguay and Paraguay.